Remifentanil Hydrochloride I · 1,536 days since initial FDA posting
Brand: REMIFENTANIL HYDROCHLORIDE
FDA lists Remifentanil Hydrochloride I as Active Shortage (Fresenius Kabi USA, LLC).
Availability on file: Unavailable
Remifentanil Hydrochloride Injection: Active Shortage
Unavailable Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Remifentanil Hydrochloride Injection
- Manufacturer
- Fresenius Kabi USA, LLC
- Dosage Form
- Injection
- Presentation
- Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)
- Package NDC
- 63323-723-03
Status & Timeline
- Status
- Active Shortage
- Availability
- Unavailable
- First Reported
- Jun 28, 2022
- Last Updated
- Feb 25, 2026
- Therapeutic Category
- Analgesia/Addiction
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Next release March 2026. Check wholesalers for inventory.
Nearby, Other Remifentanil Shortage Records
Remifentanil Hydrochloride Injection
Mylan Institutional, a Viatris Company
Injection
Remifentanil Hydrochloride Injection
Mylan Institutional, a Viatris Company
Injection
Remifentanil Hydrochloride Injection
Mylan Institutional, a Viatris Company
Injection
Remifentanil Hydrochloride Injection
Fresenius Kabi USA, LLC
Injection
Remifentanil Hydrochloride Injection
Fresenius Kabi USA, LLC
Injection
Remifentanil Hydrochloride Injection
Hikma Pharmaceuticals USA, Inc.
Injection
FDA reason on file: Next release March 2026. General shortage guidance lives on the tracker hub.